《生命科学》 2019, 31(9): 879-885

三阴性乳腺癌免疫治疗的研究进展

张　艳1， 解　伟2*，张世伟2，王风仙1，王　进2，3*

(1 上海中医药大学研究生院，上海 201203；2 上海健康医学院药学院，上海 201318；3 上海中医药大学，上海 201203)

摘　要：摘　要：乳腺癌是世界上最常见的一种女性恶性肿瘤，在中国女性肿瘤发病率中居于首位。三阴性乳腺癌(triple negative breast cancer， TNBC) 由于雌激素受体、孕激素受体及人类上皮细胞生长因子受体2 均无表达，并且具有侵袭性高、容易局部复发及远处转移等特点，是乳腺癌中最棘手的一种类型，目前临床上缺少有效的治疗方案。免疫治疗作为一种新的临床治疗手段，对TNBC 的治疗具有重大的临床意义，为患者提供新的治疗选择。该文主要从主动治疗中的免疫检查点阻断和被动治疗两个方面对TNBC 近期的免疫治疗方法作一综述。

Progress in immunotherapy for triple breast cancer

ZHANG Yan1， XIE Wei2*， ZHANG Shi-Wei2， WANG Feng-Xian1， WANG Jin2，3*

(1 Shanghai University of Traditional Chinese Medicine Graduate School， Shanghai 201203， China; 2 Shanghai University of Medical Healthy School， Shanghai 201318， China; 3 Shanghai Traditional Chinese Medicine， Shanghai 201203， China)

Abstract: Abstract: Breast cancer is the most common malignant tumor among females in the world. It ranks first in incidence of female cancer in China. Triple negative breast cancer (TNBC) is one of the most difficult malignancy to treat due to several factors， including lack of the expression of estrogen receptor (ER)， progesterone hormone receptor (PR) and human epidermal growth factor receptor 2 (HER2)， and the characteristics of high invasiveness， recrudescence and metastasis. Immunotherapy， as a new clinical treatment， offers an effective counteragent for patients with TNBC. This article focuses on the recent immunotherapy treatments for TNBC and summarizes immunological checkpoint blockade and passive therapy.